CDH1 and head and neck cancer: In head and neck cancer (HNC) cells with low expression of E-cadherin (CDH1), the treatment of 5-azacitidine diminishes the hypermethylation of CDH1, resulting in increased E-cadherin expression and decreased ferroptosis susceptibility, thereby suggesting that epigenetic reprogramming of EMT contributes to promoting ferroptosis in HNC [188].